- Home
- DSGN vs DOYU Comparison
DSGN vs DOYU Comparison
Compare DSGN & DOYU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- DOYU
- Stock Information
- Founded
- DSGN 2017
- DOYU 2014
- Country
- DSGN United States
- DOYU China
- Employees
- DSGN N/A
- DOYU N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- DOYU Computer Software: Programming Data Processing
- Sector
- DSGN Health Care
- DOYU Technology
- Exchange
- DSGN Nasdaq
- DOYU Nasdaq
- Market Cap
- DSGN 208.9M
- DOYU 195.9M
- IPO Year
- DSGN 2021
- DOYU 2019
- Fundamental
- Price
- DSGN $3.77
- DOYU $7.32
- Analyst Decision
- DSGN Hold
- DOYU Hold
- Analyst Count
- DSGN 1
- DOYU 2
- Target Price
- DSGN $4.00
- DOYU $11.00
- AVG Volume (30 Days)
- DSGN 82.2K
- DOYU 46.3K
- Earning Date
- DSGN 08-04-2025
- DOYU 05-20-2025
- Dividend Yield
- DSGN N/A
- DOYU 258.24%
- EPS Growth
- DSGN N/A
- DOYU N/A
- EPS
- DSGN N/A
- DOYU N/A
- Revenue
- DSGN N/A
- DOYU $575,786,186.00
- Revenue This Year
- DSGN N/A
- DOYU N/A
- Revenue Next Year
- DSGN N/A
- DOYU N/A
- P/E Ratio
- DSGN N/A
- DOYU N/A
- Revenue Growth
- DSGN N/A
- DOYU N/A
- 52 Week Low
- DSGN $2.60
- DOYU $5.68
- 52 Week High
- DSGN $7.77
- DOYU $20.17
- Technical
- Relative Strength Index (RSI)
- DSGN 49.66
- DOYU 73.23
- Support Level
- DSGN $3.33
- DOYU $6.35
- Resistance Level
- DSGN $4.21
- DOYU $6.58
- Average True Range (ATR)
- DSGN 0.24
- DOYU 0.27
- MACD
- DSGN -0.02
- DOYU 0.10
- Stochastic Oscillator
- DSGN 50.29
- DOYU 100.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.